CHAMPIONS ONCOLOGY, INC. Operating Expenses
CHAMPIONS ONCOLOGY, INC. (CSBR) reported Operating Expenses of $33.93 million for the 12-month period ending 2020-04-30, per its 10-K filed 2020-07-28.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2020-07-28
- CHAMPIONS ONCOLOGY, INC. operating expenses for the quarter ending 2020-04-30 was $10.66M, a 36.06% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating expenses for the quarter ending 2020-01-31 was $8.58M, a 26.16% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating expenses for the quarter ending 2019-10-31 was $7.33M, a 14.27% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating expenses for the quarter ending 2019-07-31 was $7.35M, a 27.98% increase year-over-year.
- CHAMPIONS ONCOLOGY, INC. operating expenses for fiscal 2020 was $33.93M, a 26.60% increase from fiscal 2019.
- CHAMPIONS ONCOLOGY, INC. operating expenses for fiscal 2019 was $26.80M, a 24.09% increase from fiscal 2018.
- CHAMPIONS ONCOLOGY, INC. operating expenses for fiscal 2018 was $21.59M, a 2.81% decline from fiscal 2017.
- CHAMPIONS ONCOLOGY, INC. operating expenses for fiscal 2017 was $22.22M, a 3.36% increase from fiscal 2016.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2020-04-30 | $10.66M derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-28 | $19.24M derived: sum of 2 quarters · filed 2020-07-28 | $26.57M derived: sum of 3 quarters · filed 2020-07-28 | $33.93M 10-K · filed 2020-07-28 |
| 2020-01-31 | $8.58M 10-Q · filed 2020-03-16 | $15.91M derived: sum of 2 quarters · filed 2020-03-16 | $23.27M 10-Q · filed 2020-03-16 | $31.10M derived: sum of 4 quarters · filed 2020-07-28 |
| 2019-10-31 | $7.33M 10-Q · filed 2019-12-16 | $14.69M 10-Q · filed 2019-12-16 | $22.52M derived: sum of 3 quarters · filed 2020-07-28 | $29.32M derived: sum of 4 quarters · filed 2020-07-28 |
| 2019-07-31 | $7.35M 10-Q · filed 2019-09-16 | $15.19M derived: sum of 2 quarters · filed 2020-07-28 | $21.99M derived: sum of 3 quarters · filed 2020-07-28 | $28.40M derived: sum of 4 quarters · filed 2020-07-28 |
| 2019-04-30 | $7.83M derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-28 | $14.63M derived: sum of 2 quarters · filed 2020-07-28 | $21.05M derived: sum of 3 quarters · filed 2020-07-28 | $26.80M 10-K · filed 2020-07-28 |
| 2019-01-31 | $6.80M 10-Q · filed 2020-03-16 | $13.22M derived: sum of 2 quarters · filed 2020-03-16 | $18.96M 10-Q · filed 2020-03-16 | $24.48M derived: sum of 4 quarters · filed 2020-03-16 |
| 2018-10-31 | $6.42M 10-Q · filed 2019-12-16 | $12.16M 10-Q · filed 2019-12-16 | $17.68M derived: sum of 3 quarters · filed 2019-12-16 | $22.83M derived: sum of 4 quarters · filed 2019-12-16 |
| 2018-07-31 | $5.74M 10-Q · filed 2019-09-16 | $11.27M derived: sum of 2 quarters · filed 2019-09-16 | $16.41M derived: sum of 3 quarters · filed 2019-09-16 | $21.69M derived: sum of 4 quarters · filed 2019-09-16 |
| 2018-04-30 | $5.52M derived: 10-K 12 month − 10-Q 9 month · filed 2019-07-29 | $10.67M derived: sum of 2 quarters · filed 2019-07-29 | $15.94M derived: sum of 3 quarters · filed 2019-07-29 | $21.59M 10-K · filed 2019-07-29 |
| 2018-01-31 | $5.15M 10-Q · filed 2019-03-18 | $10.42M derived: sum of 2 quarters · filed 2019-03-18 | $16.07M 10-Q · filed 2019-03-18 | $22.18M derived: sum of 4 quarters · filed 2019-03-18 |
| 2017-10-31 | $5.27M 10-Q · filed 2018-12-17 | $10.93M 10-Q · filed 2018-12-17 | $17.03M derived: sum of 3 quarters · filed 2018-12-17 | $22.00M derived: sum of 4 quarters · filed 2018-12-17 |
| 2017-07-31 | $5.65M 10-Q · filed 2018-09-14 | $11.76M derived: sum of 2 quarters · filed 2018-09-14 | $16.73M derived: sum of 3 quarters · filed 2018-09-14 | $21.68M derived: sum of 4 quarters · filed 2018-09-14 |
| 2017-04-30 | $6.11M derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-30 | $11.07M derived: sum of 2 quarters · filed 2018-07-30 | $16.02M derived: sum of 3 quarters · filed 2018-07-30 | $22.22M 10-K · filed 2018-07-30 |
| 2017-01-31 | $4.97M 10-Q · filed 2018-03-19 | $9.92M derived: sum of 2 quarters · filed 2018-03-19 | $16.11M 10-Q · filed 2018-03-19 | $21.50M derived: sum of 4 quarters · filed 2018-03-19 |
| 2016-10-31 | $4.95M 10-Q · filed 2017-12-15 | $11.14M 10-Q · filed 2017-12-15 | $16.53M derived: sum of 3 quarters · filed 2017-12-15 | $21.45M derived: sum of 4 quarters · filed 2017-12-15 |
| 2016-07-31 | $6.19M 10-Q · filed 2017-09-14 | $11.58M derived: sum of 2 quarters · filed 2017-09-14 | $16.50M derived: sum of 3 quarters · filed 2017-09-14 | $21.97M derived: sum of 4 quarters · filed 2017-09-14 |
| 2016-04-30 | $5.39M derived: 10-K 12 month − 10-Q 9 month · filed 2017-07-28 | $10.31M derived: sum of 2 quarters · filed 2017-07-28 | $15.78M derived: sum of 3 quarters · filed 2017-07-28 | $21.50M 10-K · filed 2017-07-28 |
| 2016-01-31 | $4.92M 10-Q · filed 2017-03-17 | $10.39M derived: sum of 2 quarters · filed 2017-03-17 | $16.11M 10-Q · filed 2017-03-17 | $21.75M derived: sum of 4 quarters · filed 2017-03-17 |
| 2015-10-31 | $5.46M 10-Q · filed 2016-12-14 | $11.18M 10-Q · filed 2016-12-14 | $16.83M derived: sum of 3 quarters · filed 2016-12-14 | $22.08M derived: sum of 4 quarters · filed 2016-12-14 |
| 2015-07-31 | $5.72M 10-Q · filed 2016-09-14 | $11.36M derived: sum of 2 quarters · filed 2016-09-14 | $16.61M derived: sum of 3 quarters · filed 2016-09-14 | $22.16M derived: sum of 4 quarters · filed 2016-09-14 |
| 2015-04-30 | $5.64M derived: 10-K 12 month − 10-Q 9 month · filed 2016-07-29 | $10.89M derived: sum of 2 quarters · filed 2016-07-29 | $16.44M derived: sum of 3 quarters · filed 2016-07-29 | $22.10M 10-K · filed 2016-07-29 |
| 2015-01-31 | $5.25M 10-Q · filed 2016-03-16 | $10.80M derived: sum of 2 quarters · filed 2016-03-16 | $16.46M 10-Q · filed 2016-03-16 | $21.27M derived: sum of 4 quarters · filed 2016-03-16 |
| 2014-10-31 | $5.55M 10-Q · filed 2015-12-15 | $11.18M 10-Q · filed 2015-12-15 | $16.02M derived: sum of 3 quarters · filed 2015-12-15 | $21.12M derived: sum of 4 quarters · filed 2015-12-15 |
| 2014-07-31 | $5.64M 10-Q · filed 2015-09-11 | $10.48M derived: sum of 2 quarters · filed 2015-09-11 | $15.57M derived: sum of 3 quarters · filed 2015-09-11 | $19.66M derived: sum of 4 quarters · filed 2015-09-11 |
| 2014-04-30 | $4.84M derived: 10-K 12 month − 10-Q 9 month · filed 2015-07-29 | $9.93M derived: sum of 2 quarters · filed 2015-07-29 | $14.02M derived: sum of 3 quarters · filed 2015-07-29 | $17.81M 10-K · filed 2015-07-29 |
| 2014-01-31 | $5.10M 10-Q · filed 2015-03-17 | $9.18M derived: sum of 2 quarters · filed 2015-03-17 | $12.97M 10-Q · filed 2015-03-17 | $16.80M derived: sum of 4 quarters · filed 2015-03-17 |
| 2013-10-31 | $4.08M 10-Q · filed 2014-12-15 | $7.88M 10-Q · filed 2014-12-15 | $11.70M derived: sum of 3 quarters · filed 2014-12-15 | $15.34M derived: sum of 4 quarters · filed 2014-12-15 |
| 2013-07-31 | $3.79M 10-Q · filed 2014-09-12 | $7.61M derived: sum of 2 quarters · filed 2014-09-12 | $11.25M derived: sum of 3 quarters · filed 2014-09-12 | $14.63M derived: sum of 4 quarters · filed 2014-09-12 |
| 2013-04-30 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2014-07-28 | $7.46M derived: sum of 2 quarters · filed 2014-07-28 | $10.84M derived: sum of 3 quarters · filed 2014-07-28 | $14.54M 10-K · filed 2014-07-28 |
| 2013-01-31 | $3.64M 10-Q · filed 2014-03-14 | $7.01M derived: sum of 2 quarters · filed 2014-03-14 | $10.72M 10-Q · filed 2014-03-14 | $14.70M derived: sum of 4 quarters · filed 2014-03-14 |
| 2012-10-31 | $3.37M 10-Q · filed 2013-12-13 | $7.08M 10-Q · filed 2013-12-13 | $11.06M derived: sum of 3 quarters · filed 2013-12-13 | $15.23M derived: sum of 4 quarters · filed 2013-12-13 |
| 2012-07-31 | $3.71M 10-Q · filed 2013-09-13 | $7.69M derived: sum of 2 quarters · filed 2013-09-13 | $11.86M derived: sum of 3 quarters · filed 2013-09-13 | $16.07M derived: sum of 4 quarters · filed 2013-09-13 |
| 2012-04-30 | $3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2013-07-26 | $8.15M derived: sum of 2 quarters · filed 2013-07-26 | $12.36M derived: sum of 3 quarters · filed 2013-07-26 | $16.21M 10-K · filed 2013-07-26 |
| 2012-01-31 | $4.17M 10-Q · filed 2013-03-13 | $8.38M derived: sum of 2 quarters · filed 2013-03-13 | $12.23M 10-Q · filed 2013-03-13 | $16.61M derived: sum of 4 quarters · filed 2013-03-13 |
| 2011-10-31 | $4.21M 10-Q · filed 2012-12-13 | $8.06M 10-Q · filed 2012-12-13 | $12.44M derived: sum of 3 quarters · filed 2012-12-13 | $16.03M derived: sum of 4 quarters · filed 2012-12-13 |
| 2011-07-31 | $3.85M 10-Q · filed 2012-09-12 | $8.23M derived: sum of 2 quarters · filed 2012-09-12 | $11.82M derived: sum of 3 quarters · filed 2012-09-12 | $13.77M derived: sum of 4 quarters · filed 2012-09-12 |
| 2011-04-30 | $4.38M derived: 10-K 12 month − 10-Q 9 month · filed 2012-07-18 | $7.97M derived: sum of 2 quarters · filed 2012-07-18 | $9.92M derived: sum of 3 quarters · filed 2012-07-18 | $12.12M 10-K · filed 2012-07-18 |
| 2011-01-31 | $3.59M 10-Q · filed 2012-03-14 | $5.54M derived: sum of 2 quarters · filed 2012-03-14 | $7.73M 10-Q · filed 2012-03-14 | |
| 2010-10-31 | $1.95M 10-Q · filed 2011-12-14 | $4.14M 10-Q · filed 2011-12-14 | ||
| 2010-07-31 | $2.20M 10-Q · filed 2011-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |